Accurate and timely assessment of infection severity means better patient prioritization
Every second counts in a crowded Emergency Department, where patient prioritization decisions directly impact emergency care effectiveness. Get answers fast with LIAISON® BRAHMS MR-proADM™. Our high-quality quantitative CLIA assay accurately assesses disease severity in patients with a suspected infection by quickly detecting Mid-regional pro-adrenomedullin (MR-proADM) via a single test. Now available on DiaSorin LIAISON® analyzers.
Discover how to improve ED risk stratification and triage level determination with this fast, fully-automated solution.
A powerful solution for Emergency Department (ED) decision-making LIAISON® BRAHMS MR-proADMTM is a high-quality quantitative CLIA assay that assesses disease severity in patients with a suspected infection by detecting Mid-regional pro-adrenomedullin (MRproADM) via a single test. Now available on the DiaSorin LIAISON® analyzers. Fast, accurate blood biomarker for the real-time assessment of endothelial dysfunction and organ failure in acute infection. The LIAISON® BRAHMS MR-proADMTM is an automated in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of MR-proADM in human EDTA plasma. The assay is indicated as an aid, in conjunction with clinical evaluation and other laboratory findings, to assess disease severity, disease progression or mortality risk and to guide patient disposition in: The device is intended for in vitro diagnostic use in a professional laboratory setting on the automated LIAISON® Analyzer family.
